Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Total Liabilities (2016 - 2025)

Neuroone Medical Technologies' Total Liabilities history spans 14 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 38.87% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $2.2 million, down 38.87%, while the annual FY2025 figure was $3.7 million, 18.36% down from the prior year.
  • Total Liabilities reached $2.2 million in Q4 2025 per NMTC's latest filing, down from $3.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $4.5 million in Q3 2024 to a low of $952478.0 in Q2 2022.
  • Average Total Liabilities over 5 years is $2.1 million, with a median of $1.8 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: tumbled 81.0% in 2021, then surged 153.46% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $1.2 million in 2021, then rose by 20.46% to $1.5 million in 2022, then dropped by 5.66% to $1.4 million in 2023, then soared by 153.46% to $3.6 million in 2024, then plummeted by 38.87% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Total Liabilities are $2.2 million (Q4 2025), $3.7 million (Q3 2025), and $2.6 million (Q2 2025).